TABLE OF CONTENTS
1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 OVERVIEW OF THE NORTH AMERICA TUMOR ABLATION MARKET 35
1.4 CURRENCY AND PRICING 37
1.5 LIMITATIONS 37
1.6 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 DBMR TRIPOD DATA VALIDATION MODEL 43
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46
2.6 MULTIVARIATE MODELLING 47
2.7 TYPE SEGMENT LIFELINE CURVE 48
2.8 MARKET END USERS COVERAGE GRID 49
2.9 DBMR MARKET POSITION GRID 50
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 55
4.1 PESTEL ANALYSIS 56
4.2 PORTER'S FIVE FORCES MODEL 57
5 REGULATORY FRAMEWORK 58
5.1 REGULATORY SCENARIO IN THE U.S 58
6 MARKET OVERVIEW 59
6.1 DRIVERS 61
6.1.1 RISING PREVALENCE OF CANCER NORTH AMERICALY 61
6.1.2 INCREASING INCLINATION OF SURGEONS AND PATIENTS TOWARD MINIMALLY INVASIVE PROCEDURES 61
6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS 62
6.1.4 INCREASING AWARENESS AND EDUCATION 62
6.2 RESTRAINTS 63
6.2.1 REGULATORY HURDLES FOR APPROVAL 63
6.2.2 LIMITED CLINICAL EVIDENCE 63
6.3 OPPORTUNITIES 64
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO 64
6.3.2 STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 64
6.4 CHALLENGES 65
6.4.1 TECHNICAL CHALLENGES IN TARGETING THE TUMOR 65
6.4.2 COMPETITION FROM ALTERNATIVE TREATMENT MODALITIES 65
7 NORTH AMERICA TUMOR ABLATION MARKET, BY TYPE 66
7.1 OVERVIEW 67
7.2 THERMAL ABLATION 70
7.2.1 TUMOR ABLATION SYSTEMS 71
7.2.1.1 RADIOFREQUENCY 72
7.2.1.1.1 BIPOLAR 72
7.2.1.1.2 MULTIPOLAR 72
7.2.2 IMAGE GUIDANCE PRODUCTS AND ACCESSORIES 72
7.2.2.1 CT 73
7.2.2.2 MR IMAGING 73
7.2.2.3 FLUOROSCOPY 73
7.2.2.4 OTHERS 73
7.2.2.5 MICROWAVE 73
7.2.2.6 CRYOABLATION 73
7.2.2.7 HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU) 73
7.2.2.8 LASER 73
7.3 CHEMICAL ABLATION 73
7.3.1 ETHANOL 74
7.3.2 ACETIC ACID 74
8 NORTH AMERICA TUMOR ABLATION MARKET, BY TYPES OF TREATMENT 75
8.1 OVERVIEW 76
8.2 PERCUTANEOUS 79
8.2.1 BREAST CANCER 80
8.2.2 LUNG CANCER 80
8.2.3 PROSTATE CANCER 80
8.2.4 LIVER CANCER 80
8.2.5 KIDNEY CANCER 80
8.2.6 OTHER CANCERS 80
8.3 LAPAROSCOPY 80
8.3.1 BREAST CANCER 81
8.3.2 LUNG CANCER 81
8.3.3 PROSTATE CANCER 81
8.3.4 LIVER CANCER 81
8.3.5 KIDNEY CANCER 82
8.3.6 OTHER CANCERS 82
8.4 SURGICAL 82
8.4.1 BREAST CANCER 83
8.4.2 LUNG CANCER 83
8.4.3 PROSTATE CANCER 83
8.4.4 LIVER CANCER 83
8.4.5 KIDNEY CANCER 83
8.4.6 OTHER CANCERS 83
9 NORTH AMERICA TUMOR ABLATION MARKET, BY CANCER TYPE 84
9.1 OVERVIEW 85
9.2 BREAST CANCER 88
9.3 LUNG CANCER 88
9.4 PROSTATE CANCER 89
9.5 LIVER CANCER 90
9.6 KIDNEY CANCER 91
9.7 BONE CANCER 92
9.8 OTHERS 93
10 NORTH AMERICA TUMOR ABLATION MARKET, BY END USERS 94
10.1 OVERVIEW 95
10.2 HOSPITALS 98
10.3 ONCOLOGY CENTERS 98
10.4 OTHERS 99
11 NORTH AMERICA TUMOR ABLATION MARKET, BY DISTRIBUTION CHANNEL 100
11.1 OVERVIEW 101
11.2 DIRECT TENDER 104
11.3 RETAIL SALES 104
12 NORTH AMERICA TUMOR ABLATION MARKET, BY REGION 106
12.1 NORTH AMERICA 107
12.1.1 U.S. 116
12.1.2 CANADA 121
12.1.3 MEXICO 126
13 NORTH AMERICA TUMOR ABLATION MARKET, COMPANY LANDSCAPE 131
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 131
14 SWOT ANALYSIS 132
15 COMPANY PROFILE 133
15.1 BOSTON SCIENTIFIC CORPORATION 133
15.1.1 COMPANY SNAPSHOT 133
15.1.2 REVENUE ANALYSIS 133
15.1.3 COMPANY SHARE ANALYSIS 134
15.1.4 PRODUCT PORTFOLIO 134
15.1.5 RECENT DEVELOPMENT 134
15.2 MEDTRONIC 135
15.2.1 COMPANY SNAPSHOT 135
15.2.2 REVENUE ANALYSIS 135
15.2.3 COMPANY SHARE ANALYSIS 136
15.2.4 PRODUCT PORTFOLIO 136
15.2.5 RECENT DEVELOPMENT 136
15.3 OLYMPUS 137
15.3.1 COMPANY SNAPSHOT 137
15.3.2 REVENUE ANALYSIS 137
15.3.3 COMPANY SHARE ANALYSIS 138
15.3.4 PRODUCT PORTFOLIO 138
15.3.5 RECENT DEVELOPMENT 138
15.4 STRYKER 139
15.4.1 COMPANY SNAPSHOT 139
15.4.2 REVENUE ANALYSIS 139
15.4.3 COMPANY SHARE ANALYSIS 140
15.4.4 PRODUCT PORTFOLIO 140
15.4.5 RECENT DEVELOPMENT 140
15.5 BIOTRONIK 141
15.5.1 COMPANY SNAPSHOT 141
15.5.2 COMPANY SHARE ANALYSIS 141
15.5.3 PRODUCT PORTFOLIO 142
15.5.4 RECENT DEVELOPMENT 142
15.6 ANGIODYNAMICS. 143
15.6.1 COMPANY SNAPSHOT 143
15.6.2 REVENUE ANALYSIS 143
15.6.3 PRODUCT PORTFOLIO 144
15.6.4 RECENT DEVELOPMENT 144
15.7 BIOVENTUS LLC. 145
15.7.1 COMPANY SNAPSHOT 145
15.7.2 PRODUCT PORTFOLIO 145
15.7.3 RECENT DEVELOPMENT 145
15.8 BVM MEDICAL LIMITED 146
15.8.1 COMPANY SNAPSHOT 146
15.8.2 PRODUCT PORTFOLIO 146
15.8.3 RECENT DEVELOPMENT 146
15.9 EDAP TMS 147
15.9.1 COMPANY SNAPSHOT 147
15.9.2 REVENUE ANALYSIS 147
15.9.3 PRODUCT PORTFOLIO 148
15.9.4 RECENT DEVELOPMENT 148
15.10 ETHICON, INC. 149
15.10.1 COMPANY SNAPSHOT 149
15.10.2 PRODUCT PORTFOLIO 149
15.10.3 RECENT DEVELOPMENT 149
15.11 HEALTHTRONICS, INC. 150
15.11.1 COMPANY SNAPSHOT 150
15.11.2 PRODUCT PORTFOLIO 150
15.11.3 RECENT DEVELOPMENT 150
15.12 ICECURE MEDICAL 151
15.12.1 COMPANY SNAPSHOT 151
15.12.2 REVENUE ANALYSIS 151
15.12.3 PRODUCT PORTFOLIO 152
15.12.4 RECENT DEVELOPMENT 152
15.13 INSIGHTEC. 153
15.13.1 COMPANY SNAPSHOT 153
15.13.2 PRODUCT PORTFOLIO 153
15.13.3 RECENT DEVELOPMENT 153
15.14 INTEGRA LIFESCIENCES 154
15.14.1 COMPANY SNAPSHOT 154
15.14.2 REVENUE ANALYSIS 154
15.14.3 PRODUCT PORTFOLIO 155
15.14.4 RECENT DEVELOPMENT 155
15.15 MERIT MEDICAL SYSTEMS. 156
15.15.1 COMPANY SNAPSHOT 156
15.15.2 REVENUE ANALYSIS 156
15.15.3 PRODUCT PORTFOLIO 157
15.15.4 RECENT DEVELOPMENT 157
15.16 SONABLATE CORP. 158
15.16.1 COMPANY SNAPSHOT 158
15.16.2 PRODUCT PORTFOLIO 158
15.16.3 RECENT DEVELOPMENT 158
15.17 TERUMO EUROPE NV 159
15.17.1 COMPANY SNAPSHOT 159
15.17.2 PRODUCT PORTFOLIO 159
15.17.3 RECENT DEVELOPMENT 159
16 QUESTIONNAIRE 160
17 RELATED REPORTS 163

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.